Glaukos Corporation (NYSE:GKOS) Given Consensus Rating of "Moderate Buy" by Brokerages

Glaukos Corporation (NYSE:GKOS - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $134.67.

Several analysts recently weighed in on GKOS shares. Mizuho cut their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. Piper Sandler cut their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Stephens cut their price objective on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company cut shares of Glaukos from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $160.00 to $86.00 in a research note on Thursday, May 1st. Finally, Stifel Nicolaus lowered their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st.

Institutional Trading of Glaukos

A number of institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in Glaukos during the fourth quarter worth $16,910,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Glaukos by 36.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,939 shares of the medical instruments supplier's stock valued at $2,240,000 after buying an additional 3,983 shares during the period. HighTower Advisors LLC increased its holdings in Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock valued at $495,000 after buying an additional 91 shares during the period. Swiss National Bank increased its holdings in Glaukos by 9.9% in the 4th quarter. Swiss National Bank now owns 108,100 shares of the medical instruments supplier's stock valued at $16,209,000 after buying an additional 9,700 shares during the period. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Glaukos by 12.9% in the 4th quarter. Commonwealth Equity Services LLC now owns 5,770 shares of the medical instruments supplier's stock valued at $865,000 after purchasing an additional 661 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Trading Down 2.7%

NYSE GKOS opened at $103.68 on Friday. Glaukos has a 12 month low of $77.10 and a 12 month high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.49 and a quick ratio of 5.62. The company has a market capitalization of $5.92 billion, a price-to-earnings ratio of -43.75 and a beta of 0.82. The company's fifty day moving average price is $97.18 and its two-hundred day moving average price is $114.17.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 31.40% and a negative return on equity of 10.66%. The firm had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same period in the prior year, the firm posted ($0.70) EPS. The firm's revenue was up 24.6% compared to the same quarter last year. As a group, research analysts predict that Glaukos will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.